

### 1. Physicochemical Property

Property	Value	Comment
Molecular Weight	166.97	Contain hydrogen atoms. Optimal:100~600
Volume	126.422	Van der Waals volume
Density	1.321	Density = MW / Volume
nHA	6	Number of hydrogen bond acceptors. Optimal:0~12
nHD	2	Number of hydrogen bond donors. Optimal:0~7
nRot	3	Number of rotatable bonds. Optimal:0~11
nRing	0	Number of rings. Optimal:0~6
MaxRing	0	Number of atoms in the biggest ring. Optimal:0~18
nHet	7	Number of heteroatoms. Optimal:1~15
fChar	0	Formal charge. Optimal:-4 ~4
nRig	4	Number of rigid bonds. Optimal:0~30
Flexibility	0.75	Flexibility = nRot /nRig
Stereo Centers	0	Optimal: ≤ 2
TPSA	100.9	Topological Polar Surface Area. Optimal:0~140
logS	0.163	Log of the aqueous solubility. Optimal: -4~0.5 log mol/L
logP	-1.907	Log of the octanol/water partition coefficient. Optimal: 0~3
logD	-0.906	logP at physiological pH 7.4. Optimal: 1~3

### 2. Medicinal Chemistry

2. Medicinal Chemistry			
Property	Value	Decision	Comment
QED	0.352	•	<ul> <li>A measure of drug-likeness based on the concept of desirability;</li> <li>Attractive: &gt; 0.67; unattractive: 0.49~0.67; too complex: &lt; 0.34</li> </ul>
SAscore	3.646	•	<ul> <li>■ Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules.</li> <li>■ SAscore ≥ 6, difficult to synthesize; SAscore &lt;6, easy to synthesize</li> </ul>
Fsp3	0.0	•	<ul> <li>■ The number of sp3 hybridized carbons / total carbon count, correlating with melting point and solubility.</li> <li>■ Fsp<sup>3</sup> ≥0.42 is considered a suitable value.</li> </ul>
MCE-18	0.0	•	<ul> <li>■ MCE-18 stands for medicinal chemistry evolution.</li> <li>■ MCE-18≥45 is considered a suitable value.</li> </ul>

NPscore	1.082	-	<ul> <li>Natural product-likeness score.</li> <li>This score is typically in the range from -5 to 5.</li> <li>The higher the score is, the higher the probability is that the molecule is a NP.</li> </ul>
Lipinski Rule	Accepted	•	<ul> <li>MW ≤ 500; logP ≤ 5; Hacc ≤ 10; Hdon ≤ 5</li> <li>If two properties are out of range, a poor absorption or permeability is possible, one is acceptable.</li> </ul>
Pfizer Rule	Accepted	•	logP > 3; TPSA < 75 Compounds with a high log P (>3) and low TPSA (<75) are likely to be toxic.
GSK Rule	Accepted	•	<ul> <li>MW ≤ 400; logP ≤ 4</li> <li>Compounds satisfying the GSK rule may have a more favorable ADMET profile</li> </ul>
Golden Triangle	Rejected	•	<ul> <li>■ 200 ≤ MW ≤ 50; -2 ≤ logD ≤ 5</li> <li>■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile.</li> </ul>
PAINS	0 alerts	-	Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound.
ALARM NMR	0 alerts	-	Thiol reactive compounds.
BMS	0 alerts	-	Undesirable, reactive compounds.
Chelator Rule	0 alerts	-	Chelating compounds.
3. Absorption			

### 3. Absorption

Property	Value	Decision	Comment
Caco-2 Permeability	-5.822	•	Optimal: higher than -5.15 Log unit
MDCK Permeability	0.001437		■ low permeability: $< 2 \times 10^{-6}$ cm/s ■ medium permeability: 2–20 × 10 <sup>-6</sup> cm/s ■ high passive permeability: > 20 × 10 <sup>-6</sup> cm/s
Pgp-inhibitor	0.0		<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being Pgp-inhibitor</li> </ul>
Pgp-substrate	0.0	•	<ul> <li>Category 1: substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being Pgp-substrate</li> </ul>
НІА	0.41	•	<ul> <li>Human Intestinal Absorption</li> <li>Category 1: HIA+( HIA &lt; 30%); Category 0: HIA-( HIA &lt; 30%); The output value is the probability of being HIA+</li> </ul>
F <sub>20%</sub>	0.852	•	■ 20% Bioavailability ■ Category 1: $F_{20\%}$ + (bioavailability < 20%); Category 0: $F_{20\%}^{-}$ (bioavailability ≥ 20%); The output value is the probability of being $F_{20\%}$ +

F <sub>30%</sub>	0.993	•	■ 30% Bioavailability ■ Category 1: $F_{30\%}$ + (bioavailability < 30%); Category 0: $F_{30\%}$ - (bioavailability ≥ 30%); The output value is the probability of being $F_{30\%}$ +
------------------	-------	---	--

### 4. Distribution

Property	Value	Decision	Comment
PPB	18.09%	•	<ul> <li>Plasma Protein Binding</li> <li>Optimal: &lt; 90%. Drugs with high protein-bound may have a low therapeutic index.</li> </ul>
VD	0.225	•	<ul> <li>■ Volume Distribution</li> <li>■ Optimal: 0.04-20L/kg</li> </ul>
BBB Penetration	0.826	•	<ul> <li>Blood-Brain Barrier Penetration</li> <li>Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+</li> </ul>
Fu	73.08%	•	<ul> <li>■ The fraction unbound in plasms</li> <li>■ Low: &lt;5%; Middle: 5~20%; High: &gt; 20%</li> </ul>

#### 5. Metabolism

Property	Value	Comment
CYP1A2 inhibitor	0.01	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP1A2 substrate	0.049	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C19 inhibitor	0.055	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C19 substrate	0.041	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C9 inhibitor	0.027	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C9 substrate	0.199	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2D6 inhibitor	0.045	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2D6 substrate	0.129	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP3A4 inhibitor	0.008	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP3A4 substrate	0.024	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>

### 6. Excretion

Property	Value	Decision	Comment
CL	1.825	•	<ul> <li>■ Clearance</li> <li>■ High: &gt;15 mL/min/kg; moderate: 5-15 mL/min/kg; low: &lt;5 mL/min/kg</li> </ul>
T <sub>1/2</sub>	0.845	-	<ul> <li>Category 1: long half-life ; Category 0: short half-life;</li> <li>long half-life: &gt;3h; short half-life: &lt;3h</li> <li>The output value is the probability of having long half-life.</li> </ul>

### 7. Toxicity

Property	Value	Decision	Comment
hERG Blockers	0.005	•	<ul> <li>Category 1: active; Category 0: inactive;</li> <li>The output value is the probability of being active.</li> </ul>
H-HT	0.082	•	<ul> <li>Human Hepatotoxicity</li> <li>Category 1: H-HT positive(+); Category 0: H-HT negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
DILI	0.781	•	<ul> <li>Drug Induced Liver Injury.</li> <li>Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic.</li> </ul>
AMES Toxicity	0.038	•	<ul> <li>Category 1: Ames positive(+); Category 0: Ames negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
Rat Oral Acute Toxicity	0.044	•	<ul> <li>Category 0: low-toxicity; Category 1: high-toxicity;</li> <li>The output value is the probability of being highly toxic.</li> </ul>
FDAMDD	0.024	•	<ul> <li>Maximum Recommended Daily Dose</li> <li>Category 1: FDAMDD (+); Category 0: FDAMDD (-)</li> <li>The output value is the probability of being positive.</li> </ul>
Skin Sensiti zation	0.531		<ul> <li>Category 1: Sensitizer; Category 0: Non-sensitizer;</li> <li>The output value is the probability of being sensitizer.</li> </ul>
Carcinogen city	0.06	•	<ul> <li>Category 1: carcinogens; Category 0: non-carcinogens;</li> <li>The output value is the probability of being toxic.</li> </ul>
Eye Corrosion	0.981	•	<ul> <li>Category 1: corrosives ; Category 0: noncorrosives</li> <li>The output value is the probability of being corrosives.</li> </ul>
Eye Irritation	0.99	•	<ul> <li>Category 1: irritants ; Category 0: nonirritants</li> <li>The output value is the probability of being irritants.</li> </ul>

Respiratory Toxicity	0.754	•	<ul> <li>Category 1: respiratory toxicants; Category 0: respiratory nontoxicants</li> <li>The output value is the probability of being toxic.</li> </ul>
-------------------------	-------	---	--

### 8. Environmental toxicity

Property	Value	Comment	
Bioconcentration Factors	0.31	<ul> <li>Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain.</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	
IGC <sub>50</sub>	2.457	<ul> <li>Tetrahymena pyriformis 50 percent growth inhibition concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	
LC <sub>50</sub> FM	3.759	<ul> <li>96-hour fathead minnow 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	
LC <sub>50</sub> DM	3.905	<ul> <li>48-hour daphnia magna 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	

## 9. Tox21 pathway

Property	Value	Decision	Comment
NR-AR	0.008	•	<ul> <li>Androgen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AR-LBD	0.002	•	<ul> <li>Androgen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AhR	0.001	•	<ul> <li>Aryl hydrocarbon receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-Aromatase	0.001	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER	0.02		<ul> <li>Estrogen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER-LBD	0.016	•	<ul> <li>Estrogen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-PPAR- gamma	0.001	•	<ul> <li>Peroxisome proliferator-activated receptor gamma</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ARE	0.002	•	<ul> <li>Antioxidant response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ATAD5	0.004	•	<ul> <li>ATPase family AAA domain-containing protein 5</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

SR-HSE	0.01	•	<ul> <li>Heat shock factor response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-MMP	0.003	•	<ul> <li>Mitochondrial membrane potential</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-p53	0.005	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

# 10. Toxicophore Rules

Property	Value	Comment
Acute Toxicity Rule	0 alerts	<ul> <li>20 substructures</li> <li>acute toxicity during oral administration</li> </ul>
Genotoxic Carcinogenicity Rule	0 alerts	<ul> <li>117 substructures</li> <li>carcinogenicity or mutagenicity</li> </ul>
NonGenotoxic Carcinogenicity Rule	0 alerts	<ul> <li>23 substructures</li> <li>carcinogenicity through nongenotoxic mechanisms</li> </ul>
Skin Sensitization Rule	2 alerts	<ul><li>■ 155 substructures</li><li>■ skin irritation</li></ul>
Aquatic Toxicity Rule	1 alerts	<ul> <li>99 substructures</li> <li>toxicity to liquid(water)</li> </ul>
NonBiodegradable Rule	0 alerts	<ul><li>■ 19 substructures</li><li>■ non-biodegradable</li></ul>
SureChEMBL Rule	0 alerts	<ul> <li>164 substructures</li> <li>MedChem unfriendly status</li> </ul>



O=C(O)/C(=C/F)O[P](=O)(=O)O

### 1. Physicochemical Property

Property	Value	Comment
Molecular Weight	184.97	Contain hydrogen atoms. Optimal:100~600
Volume	132.489	Van der Waals volume
Density	1.396	Density = MW / Volume
nHA	6	Number of hydrogen bond acceptors. Optimal:0~12
nHD	2	Number of hydrogen bond donors. Optimal:0~7
nRot	3	Number of rotatable bonds. Optimal:0~11
nRing	0	Number of rings. Optimal:0~6
MaxRing	0	Number of atoms in the biggest ring. Optimal:0~18
nHet	8	Number of heteroatoms. Optimal:1~15
fChar	0	Formal charge. Optimal:-4 ~4
nRig	4	Number of rigid bonds. Optimal:0~30
Flexibility	0.75	Flexibility = nRot /nRig
Stereo Centers	0	Optimal: ≤ 2
TPSA	100.9	Topological Polar Surface Area. Optimal:0~140
logS	0.245	Log of the aqueous solubility. Optimal: -4~0.5 log mol/L
logP	-1.406	Log of the octanol/water partition coefficient. Optimal: 0~3
logD	-0.891	logP at physiological pH 7.4. Optimal: 1~3

### 2. Medicinal Chemistry

Property	Value	Decision	Comment
QED	0.375	•	<ul> <li>A measure of drug-likeness based on the concept of desirability;</li> <li>Attractive: &gt; 0.67; unattractive: 0.49~0.67; too complex: &lt; 0.34</li> </ul>
SAscore	3.976	•	<ul> <li>Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules.</li> <li>SAscore ≥ 6, difficult to synthesize; SAscore &lt;6, easy to synthesize</li> </ul>
Fsp3	0.0	•	<ul> <li>■ The number of sp3 hybridized carbons / total carbon count, correlating with melting point and solubility.</li> <li>■ Fsp<sup>3</sup> ≥0.42 is considered a suitable value.</li> </ul>
MCE-18	0.0	•	<ul> <li>■ MCE-18 stands for medicinal chemistry evolution.</li> <li>■ MCE-18≥45 is considered a suitable value.</li> </ul>

NPscore	0.703	-	<ul> <li>Natural product-likeness score.</li> <li>This score is typically in the range from -5 to 5.</li> <li>The higher the score is, the higher the probability is that the molecule is a NP.</li> </ul>
Lipinski Rule	Accepted	•	<ul> <li>MW ≤ 500; logP ≤ 5; Hacc ≤ 10; Hdon ≤ 5</li> <li>If two properties are out of range, a poor absorption or permeability is possible, one is acceptable.</li> </ul>
Pfizer Rule	Accepted	•	logP > 3; TPSA < 75 Compounds with a high log P (>3) and low TPSA $(<75)$ are likely to be toxic.
GSK Rule	Accepted	•	<ul> <li>MW ≤ 400; logP ≤ 4</li> <li>Compounds satisfying the GSK rule may have a more favorable ADMET profile</li> </ul>
Golden Triangle	Rejected	•	<ul> <li>■ 200 ≤ MW ≤ 50; -2 ≤ logD ≤ 5</li> <li>■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile.</li> </ul>
PAINS	0 alerts	-	Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound.
ALARM NMR	0 alerts	-	Thiol reactive compounds.
BMS	0 alerts	-	Undesirable, reactive compounds.
Chelator Rule	0 alerts	-	Chelating compounds.
3. Absorption			

### 3. Absorption

Property	Value	Decision	Comment
Caco-2 Permeability	-5.694	•	Optimal: higher than -5.15 Log unit
MDCK Permeability	0.000656		<ul> <li>■ low permeability: &lt; 2 × 10<sup>-6</sup> cm/s</li> <li>■ medium permeability: 2–20 × 10<sup>-6</sup> cm/s</li> <li>■ high passive permeability: &gt; 20 × 10<sup>-6</sup> cm/s</li> </ul>
Pgp-inhibitor	0.0	•	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being Pgp-inhibitor</li> </ul>
Pgp-substrate	0.0	•	<ul> <li>Category 1: substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being Pgp-substrate</li> </ul>
НІА	0.557	•	<ul> <li>Human Intestinal Absorption</li> <li>Category 1: HIA+( HIA &lt; 30%); Category 0: HIA-( HIA &lt; 30%); The output value is the probability of being HIA+</li> </ul>
F <sub>20%</sub>	0.983	•	■ 20% Bioavailability ■ Category 1: $F_{20\%}^{+}$ + (bioavailability < 20%); Category 0: $F_{20\%}^{-}$ (bioavailability ≥ 20%); The output value is the probability of being $F_{20\%}^{+}$ +

F <sub>30%</sub>	0.999	•	■ 30% Bioavailability ■ Category 1: $F_{30\%}$ + (bioavailability < 30%); Category 0: $F_{30\%}$ - (bioavailability ≥ 30%); The output value is the probability of being $F_{30\%}$ +
------------------	-------	---	--

### 4. Distribution

Property	Value	Decision	Comment
PPB	28.45%	•	<ul> <li>Plasma Protein Binding</li> <li>Optimal: &lt; 90%. Drugs with high protein-bound may have a low therapeutic index.</li> </ul>
VD	0.227	•	<ul> <li>■ Volume Distribution</li> <li>■ Optimal: 0.04-20L/kg</li> </ul>
BBB Penetration	0.627	•	<ul> <li>Blood-Brain Barrier Penetration</li> <li>Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+</li> </ul>
Fu	66.78%	•	<ul> <li>■ The fraction unbound in plasms</li> <li>■ Low: &lt;5%; Middle: 5~20%; High: &gt; 20%</li> </ul>

#### 5. Metabolism

Property	Value	Comment
CYP1A2 inhibitor	0.014	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP1A2 substrate	0.064	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C19 inhibitor	0.061	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C19 substrate	0.042	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C9 inhibitor	0.016	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C9 substrate	0.46	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2D6 inhibitor	0.052	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2D6 substrate	0.13	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP3A4 inhibitor	0.008	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP3A4 substrate	0.043	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>

### 6. Excretion

Property	Value	Decision	Comment
CL	1.865	•	<ul> <li>Clearance</li> <li>High: &gt;15 mL/min/kg; moderate: 5-15 mL/min/kg; low: &lt;5 mL/min/kg</li> </ul>
T <sub>1/2</sub>	0.796	-	<ul> <li>Category 1: long half-life ; Category 0: short half-life;</li> <li>long half-life: &gt;3h; short half-life: &lt;3h</li> <li>The output value is the probability of having long half-life.</li> </ul>

### 7. Toxicity

Property	Value	Decision	Comment
hERG Blockers	0.0	•	<ul> <li>Category 1: active; Category 0: inactive;</li> <li>The output value is the probability of being active.</li> </ul>
H-HT	0.984	•	<ul> <li>Human Hepatotoxicity</li> <li>Category 1: H-HT positive(+); Category 0: H-HT negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
DILI	0.954	•	<ul> <li>Drug Induced Liver Injury.</li> <li>Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic.</li> </ul>
AMES Toxicity	0.663	•	<ul> <li>Category 1: Ames positive(+); Category 0: Ames negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
Rat Oral Acute Toxicity	0.841	•	<ul> <li>Category 0: low-toxicity; Category 1: high-toxicity;</li> <li>The output value is the probability of being highly toxic.</li> </ul>
FDAMDD	0.024	•	<ul> <li>Maximum Recommended Daily Dose</li> <li>Category 1: FDAMDD (+); Category 0: FDAMDD (-)</li> <li>The output value is the probability of being positive.</li> </ul>
Skin Sensiti zation	0.729		<ul> <li>Category 1: Sensitizer; Category 0: Non-sensitizer;</li> <li>The output value is the probability of being sensitizer.</li> </ul>
Carcinogen city	0.678	•	<ul> <li>Category 1: carcinogens; Category 0: non-carcinogens;</li> <li>The output value is the probability of being toxic.</li> </ul>
Eye Corrosion	0.964	•	<ul> <li>Category 1: corrosives ; Category 0: noncorrosives</li> <li>The output value is the probability of being corrosives.</li> </ul>
Eye Irritation	0.974	•	<ul> <li>Category 1: irritants ; Category 0: nonirritants</li> <li>The output value is the probability of being irritants.</li> </ul>

Respiratory Toxicity	0.963	•	<ul> <li>Category 1: respiratory toxicants; Category 0: respiratory nontoxicants</li> <li>The output value is the probability of being toxic.</li> </ul>
-------------------------	-------	---	--

### 8. Environmental toxicity

Property	Value	Comment		
Bioconcentration Factors	0.076	<ul> <li>Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain.</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>		
IGC <sub>50</sub>	2.285	<ul> <li>Tetrahymena pyriformis 50 percent growth inhibition concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>		
LC <sub>50</sub> FM	4.03	<ul> <li>96-hour fathead minnow 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>		
LC <sub>50</sub> DM	4.299	<ul> <li>48-hour daphnia magna 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>		

## 9. Tox21 pathway

Property	Value	Decision	Comment
NR-AR	0.005	•	<ul> <li>Androgen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AR-LBD	0.001	•	<ul> <li>Androgen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AhR	0.001	•	<ul> <li>Aryl hydrocarbon receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-Aromatase	0.0	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER	0.012	•	<ul> <li>Estrogen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER-LBD	0.005	•	<ul> <li>Estrogen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-PPAR- gamma	0.001	•	<ul> <li>Peroxisome proliferator-activated receptor gamma</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ARE	0.001	•	<ul> <li>Antioxidant response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ATAD5	0.004	•	<ul> <li>ATPase family AAA domain-containing protein 5</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

SR-HSE	0.003	•	<ul> <li>Heat shock factor response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-MMP	0.002	•	<ul> <li>Mitochondrial membrane potential</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-p53	0.003	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

# 10. Toxicophore Rules

Property	Value	Comment
Acute Toxicity Rule	0 alerts	<ul> <li>20 substructures</li> <li>acute toxicity during oral administration</li> </ul>
Genotoxic Carcinogenicity Rule	0 alerts	<ul> <li>117 substructures</li> <li>carcinogenicity or mutagenicity</li> </ul>
NonGenotoxic Carcinogenicity Rule	0 alerts	<ul> <li>23 substructures</li> <li>carcinogenicity through nongenotoxic mechanisms</li> </ul>
Skin Sensitization Rule	1 alerts	<ul> <li>155 substructures</li> <li>skin irritation</li> </ul>
Aquatic Toxicity Rule	1 alerts	<ul> <li>99 substructures</li> <li>toxicity to liquid(water)</li> </ul>
NonBiodegradable Rule	0 alerts	<ul> <li>19 substructures</li> <li>non-biodegradable</li> </ul>
SureChEMBL Rule	0 alerts	<ul> <li>164 substructures</li> <li>MedChem unfriendly status</li> </ul>



# Compound 3

O=C(O)/C(=C/Cl)O[P](=O)(=O)O

### 1. Physicochemical Property

Property	Value	Comment
Molecular Weight	200.94	Contain hydrogen atoms. Optimal:100~600
Volume	141.633	Van der Waals volume
Density	1.419	Density = MW / Volume
nHA	6	Number of hydrogen bond acceptors. Optimal:0~12
nHD	2	Number of hydrogen bond donors. Optimal:0~7
nRot	3	Number of rotatable bonds. Optimal:0~11
nRing	0	Number of rings. Optimal:0~6
MaxRing	0	Number of atoms in the biggest ring. Optimal:0~18
nHet	8	Number of heteroatoms. Optimal:1~15
fChar	0	Formal charge. Optimal:-4 ~4
nRig	4	Number of rigid bonds. Optimal:0~30
Flexibility	0.75	Flexibility = nRot /nRig
Stereo Centers	0	Optimal: ≤ 2
TPSA	100.9	Topological Polar Surface Area. Optimal:0~140
logS	0.073	Log of the aqueous solubility. Optimal: -4~0.5 log mol/L
logP	-0.612	Log of the octanol/water partition coefficient. Optimal: 0~3
logD	-0.914	logP at physiological pH 7.4. Optimal: 1~3

### 2. Medicinal Chemistry

Property	Value	Decision	Comment
QED	0.396	•	<ul> <li>A measure of drug-likeness based on the concept of desirability;</li> <li>Attractive: &gt; 0.67; unattractive: 0.49~0.67; too complex: &lt; 0.34</li> </ul>
SAscore	3.904	•	<ul> <li>Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules.</li> <li>SAscore ≥ 6, difficult to synthesize; SAscore &lt;6, easy to synthesize</li> </ul>
Fsp3	0.0	•	<ul> <li>■ The number of sp3 hybridized carbons / total carbon count, correlating with melting point and solubility.</li> <li>■ Fsp<sup>3</sup> ≥0.42 is considered a suitable value.</li> </ul>
MCE-18	0.0	•	<ul> <li>■ MCE-18 stands for medicinal chemistry evolution.</li> <li>■ MCE-18≥45 is considered a suitable value.</li> </ul>

NPscore	1.059	-	<ul> <li>Natural product-likeness score.</li> <li>This score is typically in the range from -5 to 5.</li> <li>The higher the score is, the higher the probability is that the molecule is a NP.</li> </ul>
Lipinski Rule	Accepted	•	<ul> <li>MW ≤ 500; logP ≤ 5; Hacc ≤ 10; Hdon ≤ 5</li> <li>If two properties are out of range, a poor absorption or permeability is possible, one is acceptable.</li> </ul>
Pfizer Rule	Accepted	•	logP > 3; TPSA < 75 Compounds with a high log P (>3) and low TPSA (<75) are likely to be toxic.
GSK Rule	Accepted	•	<ul> <li>MW ≤ 400; logP ≤ 4</li> <li>Compounds satisfying the GSK rule may have a more favorable ADMET profile</li> </ul>
Golden Triangle	Accepted	•	<ul> <li>■ 200 ≤ MW ≤ 50; -2 ≤ logD ≤ 5</li> <li>■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile.</li> </ul>
PAINS	0 alerts	-	Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound.
ALARM NMR	1 alerts	-	Thiol reactive compounds.
BMS	0 alerts	-	Undesirable, reactive compounds.
Chelator Rule	0 alerts	-	Chelating compounds.
3. Absorption			

### 3. Absorption

Property	Value	Decision	Comment
Caco-2 Permeability	-5.696	•	Optimal: higher than -5.15 Log unit
MDCK Permeability	0.000636		<ul> <li>■ low permeability: &lt; 2 × 10<sup>-6</sup> cm/s</li> <li>■ medium permeability: 2–20 × 10<sup>-6</sup> cm/s</li> <li>■ high passive permeability: &gt; 20 × 10<sup>-6</sup> cm/s</li> </ul>
Pgp-inhibitor	0.0	•	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being Pgp-inhibitor</li> </ul>
Pgp-substrate	0.0	•	<ul> <li>Category 1: substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being Pgp-substrate</li> </ul>
НІА	0.257	•	<ul> <li>Human Intestinal Absorption</li> <li>Category 1: HIA+( HIA &lt; 30%); Category 0: HIA-( HIA &lt; 30%); The output value is the probability of being HIA+</li> </ul>
F <sub>20%</sub>	0.945	•	■ 20% Bioavailability ■ Category 1: $F_{20\%}^{+}$ + (bioavailability < 20%); Category 0: $F_{20\%}^{-}$ (bioavailability ≥ 20%); The output value is the probability of being $F_{20\%}^{+}$ +

F <sub>30%</sub>	0.994	•	■ 30% Bioavailability ■ Category 1: $F_{30\%}$ + (bioavailability < 30%); Category 0: $F_{30\%}$ - (bioavailability ≥ 30%); The output value is the probability of being $F_{30\%}$ +
------------------	-------	---	--

### 4. Distribution

Property	Value	Decision	Comment
PPB	35.30%	•	<ul> <li>Plasma Protein Binding</li> <li>Optimal: &lt; 90%. Drugs with high protein-bound may have a low therapeutic index.</li> </ul>
VD	0.228	•	<ul> <li>■ Volume Distribution</li> <li>■ Optimal: 0.04-20L/kg</li> </ul>
BBB Penetration	0.769	•	<ul> <li>Blood-Brain Barrier Penetration</li> <li>Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+</li> </ul>
Fu	63.16%	•	<ul> <li>■ The fraction unbound in plasms</li> <li>■ Low: &lt;5%; Middle: 5~20%; High: &gt; 20%</li> </ul>

#### 5. Metabolism

Property	Value	Comment
CYP1A2 inhibitor	0.018	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP1A2 substrate	0.074	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C19 inhibitor	0.053	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C19 substrate	0.046	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C9 inhibitor	0.016	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C9 substrate	0.349	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2D6 inhibitor	0.04	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2D6 substrate	0.123	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP3A4 inhibitor	0.009	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP3A4 substrate	0.058	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>

### 6. Excretion

Property	Value	Decision	Comment
CL	1.773	•	<ul> <li>Clearance</li> <li>High: &gt;15 mL/min/kg; moderate: 5-15 mL/min/kg; low: &lt;5 mL/min/kg</li> </ul>
T <sub>1/2</sub>	0.839	-	<ul> <li>Category 1: long half-life ; Category 0: short half-life;</li> <li>long half-life: &gt;3h; short half-life: &lt;3h</li> <li>The output value is the probability of having long half-life.</li> </ul>

### 7. Toxicity

Property	Value	Decision	Comment
hERG Blockers	0.0	•	<ul> <li>Category 1: active; Category 0: inactive;</li> <li>The output value is the probability of being active.</li> </ul>
H-HT	0.97	•	<ul> <li>Human Hepatotoxicity</li> <li>Category 1: H-HT positive(+); Category 0: H-HT negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
DILI	0.976	•	<ul> <li>Drug Induced Liver Injury.</li> <li>Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic.</li> </ul>
AMES Toxicity	0.931	•	<ul> <li>Category 1: Ames positive(+); Category 0: Ames negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
Rat Oral Acute Toxicity	0.367	•	<ul> <li>Category 0: low-toxicity; Category 1: high-toxicity;</li> <li>The output value is the probability of being highly toxic.</li> </ul>
FDAMDD	0.015	•	<ul> <li>Maximum Recommended Daily Dose</li> <li>Category 1: FDAMDD (+); Category 0: FDAMDD (-)</li> <li>The output value is the probability of being positive.</li> </ul>
Skin Sensiti zation	0.775		<ul> <li>Category 1: Sensitizer; Category 0: Non-sensitizer;</li> <li>The output value is the probability of being sensitizer.</li> </ul>
Carcinogen city	0.181	•	<ul> <li>Category 1: carcinogens; Category 0: non-carcinogens;</li> <li>The output value is the probability of being toxic.</li> </ul>
Eye Corrosion	0.969	•	<ul> <li>Category 1: corrosives ; Category 0: noncorrosives</li> <li>The output value is the probability of being corrosives.</li> </ul>
Eye Irritation	0.966	•	<ul> <li>Category 1: irritants ; Category 0: nonirritants</li> <li>The output value is the probability of being irritants.</li> </ul>

Respiratory Toxicity	0.936	•	<ul> <li>Category 1: respiratory toxicants; Category 0: respiratory nontoxicants</li> <li>The output value is the probability of being toxic.</li> </ul>
-------------------------	-------	---	--

### 8. Environmental toxicity

Property	Value	Comment	
Bioconcentration Factors	0.064	<ul> <li>Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain.</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	
IGC <sub>50</sub>	2.461	<ul> <li>Tetrahymena pyriformis 50 percent growth inhibition concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	
LC <sub>50</sub> FM	4.052	<ul> <li>96-hour fathead minnow 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	
LC <sub>50</sub> DM	4.185	<ul> <li>48-hour daphnia magna 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>	

### 9. Tox21 pathway

Property	Value	Decision	Comment
NR-AR	0.004	•	<ul> <li>Androgen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AR-LBD	0.002	•	<ul> <li>Androgen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AhR	0.001	•	<ul> <li>Aryl hydrocarbon receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-Aromatase	0.0	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER	0.02	•	<ul> <li>Estrogen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER-LBD	0.008	•	<ul> <li>Estrogen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-PPAR- gamma	0.002	•	<ul> <li>Peroxisome proliferator-activated receptor gamma</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ARE	0.004	•	<ul> <li>Antioxidant response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ATAD5	0.007	•	<ul> <li>ATPase family AAA domain-containing protein 5</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

SR-HSE	0.005	•	<ul> <li>Heat shock factor response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-MMP	0.003	•	<ul> <li>Mitochondrial membrane potential</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-p53	0.011	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

# 10. Toxicophore Rules

Property	Value	Comment
Acute Toxicity Rule	0 alerts	<ul> <li>20 substructures</li> <li>acute toxicity during oral administration</li> </ul>
Genotoxic Carcinogenicity Rule	1 alerts	<ul> <li>117 substructures</li> <li>carcinogenicity or mutagenicity</li> </ul>
NonGenotoxic Carcinogenicity Rule	0 alerts	<ul> <li>23 substructures</li> <li>carcinogenicity through nongenotoxic mechanisms</li> </ul>
Skin Sensitization Rule	1 alerts	<ul><li>■ 155 substructures</li><li>■ skin irritation</li></ul>
Aquatic Toxicity Rule	1 alerts	<ul> <li>99 substructures</li> <li>toxicity to liquid(water)</li> </ul>
NonBiodegradable Rule	0 alerts	<ul><li>■ 19 substructures</li><li>■ non-biodegradable</li></ul>
SureChEMBL Rule	1 alerts	<ul> <li>164 substructures</li> <li>MedChem unfriendly status</li> </ul>



### 1. Physicochemical Property

Property	Value	Comment
Molecular Weight	169.99	Contain hydrogen atoms. Optimal:100~600
Volume	129.058	Van der Waals volume
Density	1.317	Density = MW / Volume
nHA	6	Number of hydrogen bond acceptors. Optimal:0~12
nHD	4	Number of hydrogen bond donors. Optimal:0~7
nRot	3	Number of rotatable bonds. Optimal:0~11
nRing	0	Number of rings. Optimal:0~6
MaxRing	0	Number of atoms in the biggest ring. Optimal:0~18
nHet	7	Number of heteroatoms. Optimal:1~15
fChar	0	Formal charge. Optimal:-4 ~4
nRig	2	Number of rigid bonds. Optimal:0~30
Flexibility	1.5	Flexibility = nRot /nRig
Stereo Centers	0	Optimal: ≤ 2
TPSA	107.22	Topological Polar Surface Area. Optimal:0~140
logS	1.071	Log of the aqueous solubility. Optimal: -4~0.5 log mol/L
logP	-3.094	Log of the octanol/water partition coefficient. Optimal: 0~3
logD	0.114	logP at physiological pH 7.4. Optimal: 1~3

### 2. Medicinal Chemistry

Property	Value	Decision	Comment
QED	0.367	•	<ul> <li>A measure of drug-likeness based on the concept of desirability;</li> <li>Attractive: &gt; 0.67; unattractive: 0.49~0.67; too complex: &lt; 0.34</li> </ul>
SAscore	3.655	•	<ul> <li>■ Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules.</li> <li>■ SAscore ≥ 6, difficult to synthesize; SAscore &lt;6, easy to synthesize</li> </ul>
Fsp3	0.0	•	<ul> <li>■ The number of sp3 hybridized carbons / total carbon count, correlating with melting point and solubility.</li> <li>■ Fsp<sup>3</sup> ≥0.42 is considered a suitable value.</li> </ul>
MCE-18	0.0	•	<ul> <li>■ MCE-18 stands for medicinal chemistry evolution.</li> <li>■ MCE-18≥45 is considered a suitable value.</li> </ul>

NPscore	1.173	-	<ul> <li>Natural product-likeness score.</li> <li>This score is typically in the range from -5 to 5.</li> <li>The higher the score is, the higher the probability is that the molecule is a NP.</li> </ul>	
Lipinski Rule	Accepted	•	<ul> <li>MW ≤ 500; logP ≤ 5; Hacc ≤ 10; Hdon ≤ 5</li> <li>If two properties are out of range, a poor absorption or permeability is possible, one is acceptable.</li> </ul>	
Pfizer Rule	Accepted	•	logP > 3; TPSA < 75 Compounds with a high log P (>3) and low TPSA $(<75)$ are likely to be toxic.	
GSK Rule	Accepted	•	<ul> <li>MW ≤ 400; logP ≤ 4</li> <li>Compounds satisfying the GSK rule may have a more favorable ADMET profile</li> </ul>	
Golden Triangle	Rejected	•	<ul> <li>■ 200 ≤ MW ≤ 50; -2 ≤ logD ≤ 5</li> <li>■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile.</li> </ul>	
PAINS	0 alerts	-	Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound.	
ALARM NMR	0 alerts	-	Thiol reactive compounds.	
BMS	0 alerts	-	Undesirable, reactive compounds.	
Chelator Rule	0 alerts	-	Chelating compounds.	
3. Absorption				

### 3. Absorption

Property	Value	Decision	Comment
Caco-2 Permeability	-5.881	•	Optimal: higher than -5.15 Log unit
MDCK Permeability	9e-05		<ul> <li>Iow permeability: &lt; 2 × 10<sup>-6</sup> cm/s</li> <li>medium permeability: 2–20 × 10<sup>-6</sup> cm/s</li> <li>high passive permeability: &gt; 20 × 10<sup>-6</sup> cm/s</li> </ul>
Pgp-inhibitor	0.0	•	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being Pgp-inhibitor</li> </ul>
Pgp-substrate	0.003	•	<ul> <li>Category 1: substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being Pgp-substrate</li> </ul>
НІА	0.992	•	<ul> <li>Human Intestinal Absorption</li> <li>Category 1: HIA+( HIA &lt; 30%); Category 0: HIA-( HIA &lt; 30%); The output value is the probability of being HIA+</li> </ul>
F <sub>20%</sub>	1.0	•	■ 20% Bioavailability ■ Category 1: $F_{20\%}^{+}$ + (bioavailability < 20%); Category 0: $F_{20\%}^{-}$ (bioavailability ≥ 20%); The output value is the probability of being $F_{20\%}^{+}$ +

F <sub>30%</sub>	0.997	•	■ 30% Bioavailability ■ Category 1: $F_{30\%}$ + (bioavailability < 30%); Category 0: $F_{30\%}$ - (bioavailability ≥ 30%); The output value is the probability of being $F_{30\%}$ +
------------------	-------	---	--

### 4. Distribution

Property	Value	Decision	Comment
PPB	85.82%	•	<ul> <li>Plasma Protein Binding</li> <li>Optimal: &lt; 90%. Drugs with high protein-bound may have a low therapeutic index.</li> </ul>
VD	0.287	•	<ul> <li>■ Volume Distribution</li> <li>■ Optimal: 0.04-20L/kg</li> </ul>
BBB Penetration	0.001	•	<ul> <li>Blood-Brain Barrier Penetration</li> <li>Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+</li> </ul>
Fu	22.78%	•	<ul> <li>■ The fraction unbound in plasms</li> <li>■ Low: &lt;5%; Middle: 5~20%; High: &gt; 20%</li> </ul>

#### 5. Metabolism

Property	Value	Comment
CYP1A2 inhibitor	0.003	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP1A2 substrate	0.01	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C19 inhibitor	0.034	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C19 substrate	0.032	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C9 inhibitor	0.307	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C9 substrate	0.867	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2D6 inhibitor	0.018	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2D6 substrate	0.14	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP3A4 inhibitor	0.007	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP3A4 substrate	0.0	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>

### 6. Excretion

Property	Value	Decision	Comment
CL	1.896	•	<ul> <li>■ Clearance</li> <li>■ High: &gt;15 mL/min/kg; moderate: 5-15 mL/min/kg; low: &lt;5 mL/min/kg</li> </ul>
T <sub>1/2</sub>	0.592	-	<ul> <li>Category 1: long half-life ; Category 0: short half-life;</li> <li>long half-life: &gt;3h; short half-life: &lt;3h</li> <li>The output value is the probability of having long half-life.</li> </ul>

### 7. Toxicity

Property	Value	Decision	Comment
hERG Blockers	0.011	•	<ul> <li>Category 1: active; Category 0: inactive;</li> <li>The output value is the probability of being active.</li> </ul>
H-HT	0.001	•	<ul> <li>Human Hepatotoxicity</li> <li>Category 1: H-HT positive(+); Category 0: H-HT negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
DILI	0.001	•	<ul> <li>Drug Induced Liver Injury.</li> <li>Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic.</li> </ul>
AMES Toxicity	0.007	•	<ul> <li>Category 1: Ames positive(+); Category 0: Ames negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
Rat Oral Acute Toxicity	0.007	•	<ul> <li>Category 0: low-toxicity; Category 1: high-toxicity;</li> <li>The output value is the probability of being highly toxic.</li> </ul>
FDAMDD	0.225	•	<ul> <li>Maximum Recommended Daily Dose</li> <li>Category 1: FDAMDD (+); Category 0: FDAMDD (-)</li> <li>The output value is the probability of being positive.</li> </ul>
Skin Sensiti zation	0.24	•	<ul> <li>Category 1: Sensitizer; Category 0: Non-sensitizer;</li> <li>The output value is the probability of being sensitizer.</li> </ul>
Carcinogen city	0.048	•	<ul> <li>Category 1: carcinogens; Category 0: non-carcinogens;</li> <li>The output value is the probability of being toxic.</li> </ul>
Eye Corrosion	0.999	•	<ul> <li>Category 1: corrosives ; Category 0: noncorrosives</li> <li>The output value is the probability of being corrosives.</li> </ul>
Eye Irritation	0.002	•	<ul> <li>Category 1: irritants ; Category 0: nonirritants</li> <li>The output value is the probability of being irritants.</li> </ul>

Respiratory Toxicity	0.964	•	<ul> <li>Category 1: respiratory toxicants; Category 0: respiratory nontoxicants</li> <li>The output value is the probability of being toxic.</li> </ul>
-------------------------	-------	---	--

### 8. Environmental toxicity

Property	Value	Comment
Bioconcentration Factors	-0.347	<ul> <li>Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain.</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>
IGC <sub>50</sub>	2.247	<ul> <li>Tetrahymena pyriformis 50 percent growth inhibition concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>
LC <sub>50</sub> FM	3.461	<ul> <li>96-hour fathead minnow 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>
LC <sub>50</sub> DM	1.083	<ul> <li>48-hour daphnia magna 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>

# 9. Tox21 pathway

Property	Value	Decision	Comment
NR-AR	0.0	•	<ul> <li>Androgen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AR-LBD	0.0	•	<ul> <li>Androgen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AhR	0.059	•	<ul> <li>Aryl hydrocarbon receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-Aromatase	0.001	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER	0.636		<ul> <li>Estrogen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER-LBD	0.637		<ul> <li>Estrogen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-PPAR- gamma	0.001	•	<ul> <li>Peroxisome proliferator-activated receptor gamma</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ARE	0.015	•	<ul> <li>Antioxidant response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ATAD5	0.002	•	<ul> <li>ATPase family AAA domain-containing protein 5</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

SR-HSE	0.001	•	<ul> <li>Heat shock factor response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-MMP	0.001	•	<ul> <li>Mitochondrial membrane potential</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-p53	0.003	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

# 10. Toxicophore Rules

Property	Value	Comment
Acute Toxicity Rule	0 alerts	<ul> <li>20 substructures</li> <li>acute toxicity during oral administration</li> </ul>
Genotoxic Carcinogenicity Rule	0 alerts	<ul> <li>117 substructures</li> <li>carcinogenicity or mutagenicity</li> </ul>
NonGenotoxic Carcinogenicity Rule	0 alerts	<ul> <li>23 substructures</li> <li>carcinogenicity through nongenotoxic mechanisms</li> </ul>
Skin Sensitization Rule	2 alerts	<ul><li>■ 155 substructures</li><li>■ skin irritation</li></ul>
Aquatic Toxicity Rule	2 alerts	<ul> <li>99 substructures</li> <li>toxicity to liquid(water)</li> </ul>
NonBiodegradable Rule	0 alerts	<ul><li>■ 19 substructures</li><li>■ non-biodegradable</li></ul>
SureChEMBL Rule	0 alerts	<ul> <li>164 substructures</li> <li>MedChem unfriendly status</li> </ul>



# Compound 5

NC(=O)CC(O[P](=O)(=O)O)C(=O)O

### 1. Physicochemical Property

Property	Value	Comment
Molecular Weight	212.0	Contain hydrogen atoms. Optimal:100~600
Volume	163.505	Van der Waals volume
Density	1.297	Density = MW / Volume
nHA	8	Number of hydrogen bond acceptors. Optimal:0~12
nHD	4	Number of hydrogen bond donors. Optimal:0~7
nRot	5	Number of rotatable bonds. Optimal:0~11
nRing	0	Number of rings. Optimal:0~6
MaxRing	0	Number of atoms in the biggest ring. Optimal:0~18
nHet	9	Number of heteroatoms. Optimal:1~15
fChar	0	Formal charge. Optimal:-4 ~4
nRig	4	Number of rigid bonds. Optimal:0~30
Flexibility	1.25	Flexibility = nRot /nRig
Stereo Centers	1	Optimal: ≤ 2
TPSA	143.99	Topological Polar Surface Area. Optimal:0~140
logS	-0.292	Log of the aqueous solubility. Optimal: -4~0.5 log mol/L
logP	-2.378	Log of the octanol/water partition coefficient. Optimal: 0~3
logD	-1.078	logP at physiological pH 7.4. Optimal: 1~3

### 2. Medicinal Chemistry

Property	Value	Decision	Comment
QED	0.488	•	<ul> <li>A measure of drug-likeness based on the concept of desirability;</li> <li>Attractive: &gt; 0.67; unattractive: 0.49~0.67; too complex: &lt; 0.34</li> </ul>
SAscore	3.676	•	<ul> <li>Synthetic accessibility score is designed to estimate ease of synthesis of drug-like molecules.</li> <li>SAscore ≥ 6, difficult to synthesize; SAscore &lt;6, easy to synthesize</li> </ul>
Fsp3	0.5	•	<ul> <li>■ The number of sp3 hybridized carbons / total carbon count, correlating with melting point and solubility.</li> <li>■ Fsp<sup>3</sup> ≥0.42 is considered a suitable value.</li> </ul>
MCE-18	6.0	•	<ul> <li>■ MCE-18 stands for medicinal chemistry evolution.</li> <li>■ MCE-18≥45 is considered a suitable value.</li> </ul>

NPscore	0.428	-	<ul> <li>Natural product-likeness score.</li> <li>This score is typically in the range from -5 to 5.</li> <li>The higher the score is, the higher the probability is that the molecule is a NP.</li> </ul>
Lipinski Rule	Accepted	•	<ul> <li>MW ≤ 500; logP ≤ 5; Hacc ≤ 10; Hdon ≤ 5</li> <li>If two properties are out of range, a poor absorption or permeability is possible, one is acceptable.</li> </ul>
Pfizer Rule	Accepted	•	logP > 3; TPSA < 75 Compounds with a high log P (>3) and low TPSA $(<75)$ are likely to be toxic.
GSK Rule	Accepted	•	<ul> <li>MW ≤ 400; logP ≤ 4</li> <li>Compounds satisfying the GSK rule may have a more favorable ADMET profile</li> </ul>
Golden Triangle	Accepted	•	<ul> <li>■ 200 ≤ MW ≤ 50; -2 ≤ logD ≤ 5</li> <li>■ Compounds satisfying the Golden Triangle rule may have a more favorable ADMET profile.</li> </ul>
PAINS	0 alerts	-	Pan Assay Interference Compounds, frequent hitters, Alpha-screen artifacts and reactive compound.
ALARM NMR	0 alerts	-	Thiol reactive compounds.
BMS	0 alerts	-	Undesirable, reactive compounds.
Chelator Rule	0 alerts	-	Chelating compounds.
3. Absorption			

### 3. Absorption

Property	Value	Decision	Comment
Caco-2 Permeability	-6.152	•	Optimal: higher than -5.15 Log unit
MDCK Permeability	0.002665		<ul> <li>■ low permeability: &lt; 2 × 10<sup>-6</sup> cm/s</li> <li>■ medium permeability: 2–20 × 10<sup>-6</sup> cm/s</li> <li>■ high passive permeability: &gt; 20 × 10<sup>-6</sup> cm/s</li> </ul>
Pgp-inhibitor	0.0	•	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being Pgp-inhibitor</li> </ul>
Pgp-substrate	0.004	•	<ul> <li>Category 1: substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being Pgp-substrate</li> </ul>
НІА	0.027	•	<ul> <li>Human Intestinal Absorption</li> <li>Category 1: HIA+( HIA &lt; 30%); Category 0: HIA-( HIA &lt; 30%); The output value is the probability of being HIA+</li> </ul>
F <sub>20%</sub>	0.843	•	■ 20% Bioavailability ■ Category 1: $F_{20\%}^{+}$ + (bioavailability < 20%); Category 0: $F_{20\%}^{-}$ (bioavailability ≥ 20%); The output value is the probability of being $F_{20\%}^{+}$ +

F <sub>30%</sub>	0.987	•	■ 30% Bioavailability ■ Category 1: $F_{30\%}$ + (bioavailability < 30%); Category 0: $F_{30\%}$ - (bioavailability ≥ 30%); The output value is the probability of being $F_{30\%}$ +
------------------	-------	---	--

### 4. Distribution

Property	Value	Decision	Comment
PPB	7.939%	•	<ul> <li>Plasma Protein Binding</li> <li>Optimal: &lt; 90%. Drugs with high protein-bound may have a low therapeutic index.</li> </ul>
VD	0.211	•	<ul> <li>■ Volume Distribution</li> <li>■ Optimal: 0.04-20L/kg</li> </ul>
BBB Penetration	0.961	•	<ul> <li>Blood-Brain Barrier Penetration</li> <li>Category 1: BBB+; Category 0: BBB-; The output value is the probability of being BBB+</li> </ul>
Fu	89.67%	•	<ul> <li>■ The fraction unbound in plasms</li> <li>■ Low: &lt;5%; Middle: 5~20%; High: &gt; 20%</li> </ul>

#### 5. Metabolism

Property	Value	Comment
CYP1A2 inhibitor	0.003	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP1A2 substrate	0.04	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C19 inhibitor	0.038	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C19 substrate	0.037	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2C9 inhibitor	0.012	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2C9 substrate	0.801	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP2D6 inhibitor	0.038	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP2D6 substrate	0.108	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>
CYP3A4 inhibitor	0.005	<ul> <li>Category 1: Inhibitor; Category 0: Non-inhibitor;</li> <li>The output value is the probability of being inhibitor.</li> </ul>
CYP3A4 substrate	0.004	<ul> <li>Category 1: Substrate; Category 0: Non-substrate;</li> <li>The output value is the probability of being substrate.</li> </ul>

### 6. Excretion

Property	Value	Decision	Comment
CL	1.721	•	<ul> <li>Clearance</li> <li>High: &gt;15 mL/min/kg; moderate: 5-15 mL/min/kg; low: &lt;5 mL/min/kg</li> </ul>
T <sub>1/2</sub>	0.588	-	<ul> <li>Category 1: long half-life ; Category 0: short half-life;</li> <li>long half-life: &gt;3h; short half-life: &lt;3h</li> <li>The output value is the probability of having long half-life.</li> </ul>

### 7. Toxicity

Property	Value	Decision	Comment
hERG Blockers	0.009	•	<ul> <li>Category 1: active; Category 0: inactive;</li> <li>The output value is the probability of being active.</li> </ul>
H-HT	0.061	•	<ul> <li>Human Hepatotoxicity</li> <li>Category 1: H-HT positive(+); Category 0: H-HT negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
DILI	0.112	•	<ul> <li>Drug Induced Liver Injury.</li> <li>Category 1: drugs with a high risk of DILI; Category 0: drugs with no risk of DILI. The output value is the probability of being toxic.</li> </ul>
AMES Toxicity	0.019	•	<ul> <li>Category 1: Ames positive(+); Category 0: Ames negative(-);</li> <li>The output value is the probability of being toxic.</li> </ul>
Rat Oral Acute Toxicity	0.001	•	<ul> <li>Category 0: low-toxicity; Category 1: high-toxicity;</li> <li>The output value is the probability of being highly toxic.</li> </ul>
FDAMDD	0.027	•	<ul> <li>Maximum Recommended Daily Dose</li> <li>Category 1: FDAMDD (+); Category 0: FDAMDD (-)</li> <li>The output value is the probability of being positive.</li> </ul>
Skin Sensiti zation	0.305		<ul> <li>Category 1: Sensitizer; Category 0: Non-sensitizer;</li> <li>The output value is the probability of being sensitizer.</li> </ul>
Carcinogen city	0.015	•	<ul> <li>Category 1: carcinogens; Category 0: non-carcinogens;</li> <li>The output value is the probability of being toxic.</li> </ul>
Eye Corrosion	0.26	•	<ul> <li>Category 1: corrosives ; Category 0: noncorrosives</li> <li>The output value is the probability of being corrosives.</li> </ul>
Eye Irritation	0.846	•	<ul> <li>Category 1: irritants ; Category 0: nonirritants</li> <li>The output value is the probability of being irritants.</li> </ul>

Respiratory Toxicity	0.162	•	<ul> <li>Category 1: respiratory toxicants; Category 0: respiratory nontoxicants</li> <li>The output value is the probability of being toxic.</li> </ul>
-------------------------	-------	---	--

### 8. Environmental toxicity

Property	Value	Comment
Bioconcentration Factors	0.086	<ul> <li>Bioconcentration factors are used for considering secondary poisoning potential and assessing risks to human health via the food chain.</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>
IGC <sub>50</sub>	2.12	<ul> <li>Tetrahymena pyriformis 50 percent growth inhibition concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>
LC <sub>50</sub> FM	3.767	<ul> <li>96-hour fathead minnow 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>
LC <sub>50</sub> DM	3.012	<ul> <li>48-hour daphnia magna 50 percent lethal concentration</li> <li>The unit is -log10[(mg/L)/(1000*MW)]</li> </ul>

# 9. Tox21 pathway

Property	Value	Decision	Comment
NR-AR	0.011	•	<ul> <li>Androgen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AR-LBD	0.005	•	<ul> <li>Androgen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-AhR	0.0	•	<ul> <li>Aryl hydrocarbon receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-Aromatase	0.0	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER	0.034	•	<ul> <li>Estrogen receptor</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-ER-LBD	0.255	•	<ul> <li>Estrogen receptor ligand-binding domain</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
NR-PPAR- gamma	0.003	•	<ul> <li>Peroxisome proliferator-activated receptor gamma</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ARE	0.004	•	<ul> <li>Antioxidant response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-ATAD5	0.004	•	<ul> <li>ATPase family AAA domain-containing protein 5</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

SR-HSE	0.004	•	<ul> <li>Heat shock factor response element</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-MMP	0.005	•	<ul> <li>Mitochondrial membrane potential</li> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>
SR-p53	0.009	•	<ul> <li>Category 1: actives ; Category 0: inactives;</li> <li>The output value is the probability of being active.</li> </ul>

# 10. Toxicophore Rules

Property	Value	Comment
Acute Toxicity Rule	0 alerts	<ul> <li>20 substructures</li> <li>acute toxicity during oral administration</li> </ul>
Genotoxic Carcinogenicity Rule	0 alerts	<ul> <li>117 substructures</li> <li>carcinogenicity or mutagenicity</li> </ul>
NonGenotoxic Carcinogenicity Rule	0 alerts	<ul> <li>23 substructures</li> <li>carcinogenicity through nongenotoxic mechanisms</li> </ul>
Skin Sensitization Rule	0 alerts	<ul> <li>155 substructures</li> <li>skin irritation</li> </ul>
Aquatic Toxicity Rule	0 alerts	<ul> <li>99 substructures</li> <li>toxicity to liquid(water)</li> </ul>
NonBiodegradable Rule	0 alerts	<ul><li>■ 19 substructures</li><li>■ non-biodegradable</li></ul>
SureChEMBL Rule	0 alerts	<ul> <li>164 substructures</li> <li>MedChem unfriendly status</li> </ul>